Abstract:Enveloped virus vaccines can be damaged by high osmotic strength solutions, such as those used to protect the vaccine antigen during drying, which contain high concentrations of sugars. We therefore studied shrinkage and activity loss of whole inactivated influenza virus in hyperosmotic solutions and used those findings to improve vaccine coating of microneedle patches for influenza vaccination. Using stopped-flow light scattering analysis, we found that the virus underwent an initial shrinkage on the order of 10% by volume within 5 s upon exposure to a hyperosmotic stress difference of 217 milliosmolarity. During this shrinkage, the virus envelope had very low osmotic water permeability (1 - 6×10-4 cm s-1) and high Arrhenius activation energy (Ea = 15.0 kcal mol-1), indicating that the water molecules diffused through the viral lipid membranes. After a quasi-stable state of approximately 20 s to 2 min, depending on the species and hypertonic osmotic strength difference of disaccharides, there was a second phase of viral shrinkage. At the highest osmotic strengths, this led to an undulating light scattering profile that appeared to be related to perturbation of the viral envelope resulting in loss of virus activity, as determined by in vitro hemagglutination measurements and in vivo immunogenicity studies in mice. Addition of carboxymethyl cellulose effectively prevented vaccine activity loss in vitro and in vivo, believed to be due to increasing the viscosity of concentrated sugar solution and thereby reducing osmotic stress during coating of microneedles. These results suggest that hyperosmotic solutions can cause biphasic shrinkage of whole inactivated influenza virus which can damage vaccine activity at high osmotic strength and that addition of a viscosity enhancer to the vaccine coating solution can prevent osmotically driven damage and thereby enable preparation of stable microneedle coating formulations for vaccination.

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity

Stability of Influenza Vaccine Coated Onto Microneedles.

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin.

Influenza Immunization with Trehalose-Stabilized Virus-Like Particle Vaccine Using Microneedles.

Enhanced Memory Responses to Seasonal H1n1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles

Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage

Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch

Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization

Improved Influenza Vaccination in the Skin Using Vaccine Coated Microneedles

Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles

Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine

Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays.

Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination

Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles

Microneedle Delivery of Trivalent Influenza Vaccine to the Skin Induces Long-Term Cross-Protection

Egg microneedles for transdermal vaccination of inactivated influenza virus

Combination of Microneedles and MF59 Adjuvant As a Simple Approach to Enhance Transcutaneous Immunization.

Microneedle Delivery of H5n1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice